Quarterly ResultAug 6, 2026, 04:21 PM
Apyx Medical Q2 Revenue $13.9M, Net Loss Narrows to $3.2M
AI Summary
Apyx Medical Corporation reported a 22% increase in total revenue to $13.9 million for the second quarter ended June 30, 2026, primarily driven by 28% growth in its Surgical Aesthetics segment. The company's net loss attributable to stockholders narrowed to $3.2 million from $3.8 million in the prior year period. Apyx Medical also announced the successful limited launch of the power liposuction handpiece for its AYON platform and reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million.
Key Highlights
- Total revenue increased 22% to $13.9 million in Q2 2026.
- Surgical Aesthetics revenue grew 28% to $12.4 million.
- OEM revenue decreased 12% to $1.5 million.
- Net loss attributable to stockholders narrowed to $3.2 million.
- Adjusted EBITDA loss improved to $0.7 million.
- Reaffirmed FY2026 total revenue guidance of $59.0M-$60.0M.
- Successfully commenced limited launch of AYON power liposuction handpiece.
- Cash and cash equivalents were $27.6 million as of June 30, 2026.
Price Impact
More from APYX